The company has not filed an annual or quarterly report since its Q2 FY2021 10-Q, filed Aug 5, 2021. Its latest SEC filing is a SC 13G/A from Feb 14, 2022.
10-Q for Q2 FY2021, filed Aug 5, 2021
The sections below describe the company as of the FY2020 annual report.
Develops biologic treatments for dogs and cats and commercializes veterinary medicines for veterinarians through partners.
10-K for FY2020, filed Mar 16, 2021We are a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Our mission is to…View ↗
On March 16, 2020, we announced we will further prioritize biologics programs for dogs and cats and rely primarily on a partnership-focused…View ↗
We believe there are significant unmet medical needs for pets, and that the pet therapeutics segment of the animal health industry is…View ↗
Distributors and other buyers pay for finished products when delivered. Partners pay for manufacturing work as it progresses, licensing services or milestones, and royalties tied to product sales; asset sales bring a one-time cash payment.
10-K for FY2020, filed Mar 16, 2021Revenue for product sales is recognized when control of the finished goods is transferred to the customer, net of applicable reserves for…View ↗
For contract manufacturing service, revenue is recognized over time. Control of the finished manufactured products is transferred at a…View ↗
Partner licensing revenue consists of revenue that compensates us for services performed, such as formulation, process development, and…View ↗
We recognize royalty revenue in connection with licenses granted under license and development arrangements with partners. Royalties are…View ↗
In March 2020, we entered into an Asset Purchase Agreement to sell Mirataz to Dechra for a cash purchase price of $43 million. On April 15…View ↗
$42.2M
10-K for FY2020, filed Mar 16, 2021
$42.2M ↗
Distributors buy products for resale to veterinarians, clinics and animal hospitals; licensing partners and other third parties work with the company on product development and manufacturing. The company plans to commercialize dog and cat biologics through partners and distributors.
10-K for FY2020, filed Mar 16, 2021Our product revenues consist of sales of Mirataz and Zimeta. We account for a contract with a customer when there is a legally enforceable…View ↗
The manufacturing revenue stream generally represents revenue from the manufacturing of customer product(s). Under a manufacturing…View ↗
We believe there are significant unmet medical needs for pets, and that the pet therapeutics segment of the animal health industry is…View ↗
No. It lost $21.8M in .
10-K for FY2020, filed Mar 16, 2021
10-Q for Q2 FY2021, filed Aug 5, 2021
−$9.1MView ↗
8-K, filed Aug 30, 2021
The Merger became effective on August 27, 2021, when the certificate of merger of KindredBio and Merger Sub was filed with the Secretary of…View ↗
Pipeline and sales strategy
The earlier report described a mixed small-molecule and biologics pipeline for dogs, cats and horses, with a planned direct U.S. sales force. The latest report focuses on dog and cat biologics, stops most small-molecule development for those species, and relies more on commercial partners.
10-K for FY2017, filed Mar 1, 2018 10-K for FY2020, filed Mar 16, 2021We are a pre-commercialization biopharmaceutical company focused on saving and improving the lives of pets. Our mission is to bring to our…View ↗
We plan to commercialize our feline, equine and canine products in the United States through a direct sales force complemented by selected…View ↗
Our current product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses, with focus…View ↗
On March 16, 2020, we announced we will further prioritize biologics programs for dogs and cats and rely primarily on a partnership-focused…View ↗
On March 16, 2020, KindredBio announced the discontinuation of the development of canine and feline small molecule candidates as we…View ↗
We believe there are significant unmet medical needs for pets, and that the pet therapeutics segment of the animal health industry is…View ↗
Competes with Merck, Boehringer Ingelheim, Elanco Animal Health, Zoetis, Virbac Group, Ceva Animal Health, Dechra Pharmaceuticals, Zomedica, Scout Bio, and Anivive Lifesciences
10-K for FY2020, filed Mar 16, 2021Large animal health companies include Merck Animal Health, the animal health division of Merck & Co., Inc.; Boehringer Ingelheim Animal…View ↗
Loading...
